McIlrath & Eck’s Organon & Co OGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.58K Sell
264
-7
-3% -$53 ﹤0.01% 1446
2025
Q4
$1.94K Sell
271
-3
-1% -$24 ﹤0.01% 893
2025
Q3
$2.93K Hold
274
﹤0.01% 811
2025
Q2
$2.65K Sell
274
-12
-4% -$124 ﹤0.01% 809
2025
Q1
$4.26K Sell
286
-24
-8% -$369 ﹤0.01% 749
2024
Q4
$4.63K Hold
310
﹤0.01% 771
2024
Q3
$5.93K Sell
310
-5
-2% -$104 ﹤0.01% 717
2024
Q2
$6.52K Sell
315
-27
-8% -$537 ﹤0.01% 674
2024
Q1
$6.43K Buy
342
+14
+4% +$240 ﹤0.01% 681
2023
Q4
$4.73K Sell
328
-3
-0.9% -$41 ﹤0.01% 680
2023
Q3
$5.75K Hold
331
﹤0.01% 627
2023
Q2
$6.89K Sell
331
-6
-2% -$130 ﹤0.01% 613
2023
Q1
$7.93K Hold
337
﹤0.01% 589
2022
Q4
$9.41K Sell
337
-34
-9% -$869 ﹤0.01% 548
2022
Q3
$9K Sell
371
-29
-7% -$876 ﹤0.01% 557
2022
Q2
$14K Sell
400
-16
-4% -$560 ﹤0.01% 448
2022
Q1
$15K Sell
416
-5
-1% -$171 ﹤0.01% 452
2021
Q4
$13K Sell
421
-40
-9% -$1.3K ﹤0.01% 495
2021
Q3
$15K Sell
461
-11
-2% -$352 ﹤0.01% 454
2021
Q2
$14K Buy
+472
New +$15.5K ﹤0.01% 465

Other funds holding OGN

McIlrath & Eck's OGN Position: Q1 2026 in Review

McIlrath & Eck reduced its Organon & Co (OGN) stake by 2.6% in Q1 2026, selling an estimated $53 and leaving 264 shares worth $1.58K. The position accounts for ﹤0.01% of the portfolio, ranked #1446.

McIlrath & Eck first reported a position in OGN in Q2 2021 and has held it in 20 quarters since. The position peaked at $15K in Q1 2022. 603 funds tracked by Wall St. Rank hold OGN as of Q1 2026.

  • McIlrath & Eck held 264 shares of Organon & Co worth $1.58K as of Q1 2026.
  • McIlrath & Eck sold 7 Organon & Co shares in Q1 2026, an estimated $53.
  • Organon & Co made up ﹤0.01% of McIlrath & Eck's portfolio in Q1 2026, its #1446 holding.
  • McIlrath & Eck first reported a position in Organon & Co in Q2 2021 and has held it in 20 quarters since.
  • McIlrath & Eck's Organon & Co position peaked at $15K in Q1 2022.
  • 603 funds tracked by Wall St. Rank held Organon & Co as of Q1 2026.

Based on McIlrath & Eck's 13F filing for Q1 2026, filed 19 May 2026.